Thrombotic events can be a risk in this population and this possibility should be carefully weighed against the benefit to be derived from the treatment in this patient group.
Seoses sellega, et neil patsientidel on suurem trombembooliliste tüsistuste oht, tuleb riski/ kasulikkuse suhet enne ravi alustamist hoolikalt kaaluda.